QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.092312v1 316/1/189    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Danzeisen, R. Articles by Kussmaul, L. Search for Related Content PubMed PubMed Citation Articles by Danzeisen, R. Articles by Kussmaul, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antioxidants Hazardous Substances DB HYDROGEN PEROXIDE

NEUROPHARMACOLOGY

Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole Dihydrochloride]

Department of Neurology, University of Ulm, Ulm, Germany (R.D., B.S., A.C.L.); Department of Central Nervous System Research, Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (F.G., E.B., B.H., C.D.-C., L.K.); Department of Medical Data Services, Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (V.K.); Department of Drug Discovery Support, Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (K.K.); and Institute of Clinical Chemistry and Pathological Biochemistry, Department of Pathological Biochemistry, Otto-von-Guericke-University, Magdeburg, Germany (L.S.)

Pramipexole has been shown to possess neuroprotective properties in vitro that are partly independent of its dopaminergic agonism. The site of neuroprotective action is still unknown. Using [³H]pramipexole, we show that the drug enters and accumulates in cells and mitochondria. Detoxification of reactive oxygen species (ROS) by pramipexole is shown in vitro and in vivo by evaluating mitochondrial ROS release and aconitase-2 activity, respectively. Pramipexole and its (+)-enantiomer SND919CL2X [low-affinity dopamine agonist; (+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole dihydrochloride] possess equipotent efficacy toward hydrogen peroxide and nitric oxide generated in vitro and inhibit cell death in glutathione-depleted neuroblastoma cells. IC₅₀ values ranged from 15 to 1000 µM, consistent with the reactivity of the respective radical and the compartmentalization of ROS generation and ROS detoxification. Finally, both compounds were tested in superoxide dismutase 1-G93A mice, a model of familial amyotrophic lateral sclerosis. SND919CL2X (100 mg/kg) prolongs survival time and preserves motor function in contrast to pramipexole (3 mg/kg), which shows an increase in running wheel activity before disease onset, presumably caused by the dopaminergic agonism. We conclude that both enantiomers, in addition to their dopaminergic activity, are able to confer neuroprotective effects by their ability to accumulate in brain, cells, and mitochondria where they detoxify ROS. However, a clinical use of pramipexole as a mitochondria-targeted antioxidant is unlikely, because the high doses needed for antioxidative action in vitro are not accessible in vivo due to dopaminergic side effects. In contrast, SND919CL2X may represent the prototype of a mitochondria-targeted neuroprotectant because it has the same antioxidative properties without causing adverse effects.

Address correspondence to: Lothar Kussmaul, Department of Central Nervous System Research, Boehringer-Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strae 65, 88397 Biberach an der Riss, Germany. E-mail: lothar.kussmaul{at}bc.boehringer-ingelheim.com

This article has been cited by other articles:

				M. Watabe and T. Nakaki Mitochondrial Complex I Inhibitor Rotenone-Elicited Dopamine Redistribution from Vesicles to Cytosol in Human Dopaminergic SH-SY5Y Cells J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 499 - 507. [Abstract] [Full Text] [PDF]